Vedi l'allegato 653320
www.gov.uk
There is an increased risk of myocarditis (inflammation of the heart muscle)
and pericarditis (inflammation of the lining outside the heart)
after vaccination with COVID-19 mRNA Vaccine BNT162b2 (see section 4). These conditions can develop within just a few days after vaccination and have primarily occurred within 14 days.
They have been observed more often after the second vaccination, and more often in younger males. Following vaccination, you should be alert to signs of myocarditis and pericarditis, such as breathlessness, palpitations and chest pain, and seek immediate medical attention should these occur.
As with any vaccine, COVID-19 mRNA Vaccine BNT162b2
may not fully protect all those who receive it. No data are currently available in individuals with a weakened immune system or who are taking chronic treatment that suppresses or prevents immune responses.
If you are immunocompromised and receive an additional dose of mRNA Vaccine BNT162b2, it may still not provide full immunity to COVID-19 and you should continue to maintain physical precautions to help prevent COVID-19.
Children
COVID-19 mRNA Vaccine BNT162b2
is not recommended for children under 12 years
COME VE LO DEVONO SCRIVERE?
COSI'?
o così
in grassetto
o sottolineato?
.
.
.
.